J&J Oncology Head Confident About Fast-Tracked Daratumumab's Chances
This article was originally published in Scrip
Johnson & Johnson says it is increasingly confident its anti-CD38 monoclonal antibody daratumumab will get final approval in both the US and Europe after being fast-tracked by regulators in both regions for treating multiple myeloma, an incurable blood cancer.
You may also be interested in...
Germany’s Merck has licensed exclusive rights to develop and sell Debiopharm’s potential first-in-class inhibitor of apoptosis proteins (IAP) antagonist, targeting head and neck cancers.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.